People with asthma and other breathing conditions are urged to take extra care through the coming days as filthy air smothers Britain and the pollen count soars. Rising temperatures will spur trees to spew out clouds of irritant pollen as a cloud of traffic smog and factory fumes blows in from the Continent. The combination of airborne toxins and allergens threatens to trigger so-called ‘grey fever’ in millions of summer allergy sufferers.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
